Diazon Pharmaceuticals

Diazon Pharmaceuticals Inc. develops anti-cancer drugs. The company provides DZ-2384, a microtubule-targeting agent for the treatment of potentially various cancers. Its DZ-2384 exhibits a unique binding mode at the Vinca site of tubulin, significantly impacting microtubule dynamics and structure, translating into potent anti-tumor efficacy and a superior safety margin; inhibiting the growth rate of microtubules; altering microtubule dynamics in a manner consistent with microtubule preservation. ULE networks in interphase cells and primary cortical neurons; as a single agent, it demonstrates effective anti-tumor activity in xenograft, patient-derived xenograft, and genetically engineered mouse models. Diazon Pharmaceuticals Inc. was founded in 2013 and is headquartered in Montreal, Canada.